Clinical Trial: Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.

Brief Summary: The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.

Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Current Primary Outcome: To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.

Original Primary Outcome: To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparision to Paroxetine.

Current Secondary Outcome: Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine.

Original Secondary Outcome: Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparision to Paroxetine.

Information By: Wyeth is now a wholly owned subsidiary of Pfizer

Dates:
Date Received: September 12, 2005
Date Started: January 2005
Date Completion:
Last Updated: April 1, 2010
Last Verified: March 2010